Biosimilar brand buy to help Intas Pharma take on biggies

Biosimilar brand buy to help Intas Pharma take on biggies
Economic Times
Published onEconomic Times
Publish Date6 February 2025
Reading time1 Min

Share on Social Links

Category

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

​In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.

Intas Pharmaceuticals' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon, Amgen, Pfizer, Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.



Tags

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Stay Connected, Stay Informed –

Join Our

WhatsApp

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Pre Ipo

Upcoming IPO

Upcoming IPO

Unicorn

Unicorn